See-Mode raises US$7M Series A to help clinicians better predict risk of stroke, vascular diseases
Singapore- and Australia-based medtech startup, See-Mode Technologies, announced today it has raised a US$7 million Series A funding, led by Mass Mutual Ventures Southeast Asia (MMV SEA).
Other participants in the round include existing investors Blackbird Ventures, Cocoon Capital, Entrepreneur First, and SGInnovate, besides a group of angels.
This brings See-Mode’s total funding to date to US$8 million, which also included a US$1M seed round raised in 2018.
As per a press statement, the company plans to use the fresh funds for expansion into the American and European markets, R&D, hire people and build its sales and business development team.
It is also broadening its partnerships to more research institutions around the world.
Founded in 2017 by Dr Mohammadzadeh and Dr Sadaf Monajemi, See-Mode uses Artificial Intelligence (AI) to help clinicians better predict the risk of stroke and vascular diseases.
Around the world, stroke remains a leading cause of death and disability. To help clinicians better predict the risk of stroke and vascular diseases, See-Mode is developing novel solutions to improve the analysis of routinely collected medical images such as ultrasound, CT and MRI scans.
See-Mode’s software applies AI and computational models on these medical images, allowing clinicians to obtain critical stroke risk factors that may not be accessible in current clinical practice.
This allows doctors to efficiently decide on the optimal treatment for patients, improving patient care and outcomes, without the need for additional tests.
Its debut product, Augmented Vascular Analysis (AVA), is a medical AI software for automated analysis and reporting of vascular ultrasound scans.
“20 per cent of stroke patients go on to have another stroke within five years. Tackling stroke is no small feat. We are lucky to be working with an outstanding group of clinicians from leading research institutions globally to further validate our products,” Mohammadzadeh said.
AVA is awaiting regulatory approval in several markets, including Europe and the US.
Additionally, the company is building two other new products — to detect vulnerable plaque using Machine Learning and to identify high-risk blood flow using computational modelling.